These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 34935688)

  • 21. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.
    D'Amico L; Menzel U; Prummer M; Müller P; Buchi M; Kashyap A; Haessler U; Yermanos A; Gébleux R; Briendl M; Hell T; Wolter FI; Beerli RR; Truxova I; Radek Š; Vlajnic T; Grawunder U; Reddy S; Zippelius A
    J Immunother Cancer; 2019 Jan; 7(1):16. PubMed ID: 30665463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
    Nicolò E; Repetto M; Boscolo Bielo L; Tarantino P; Curigliano G
    Cancer J; 2022 Nov-Dec 01; 28(6):436-445. PubMed ID: 36383906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
    Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
    MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Advances in the treatment of anti-HER-2 antibody drug conjugates in pan-tumor with low HER-2 expression].
    Wei T; Yuan P
    Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):211-220. PubMed ID: 38494768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
    Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
    Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress.
    Rosner S; Valdivia A; Hoe HJ; Murray JC; Levy B; Felip E; Solomon BJ
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e389968. PubMed ID: 37163707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class.
    Marks JA; Wilgucki M; Liu SV; Reuss JE
    Curr Oncol Rep; 2022 Dec; 24(12):1829-1841. PubMed ID: 36197593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation and Characterization of SORT1-Targeted Antibody-Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor.
    Zhuang W; Zhang W; Xie L; Wang L; Li Y; Wang Z; Zhang A; Qiu H; Feng J; Zhang B; Hu Y
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and Emerging Role of Antibody-Drug Conjugates in HER2-Negative Breast Cancer.
    Abelman RO; Keenan JC; Ryan PK; Spring LM; Bardia A
    Hematol Oncol Clin North Am; 2023 Feb; 37(1):151-167. PubMed ID: 36435607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2).
    Seyedmirzaei H; Keshavarz-Fathi M; Razi S; Gity M; Rezaei N
    J Oncol Pharm Pract; 2021 Jul; 27(5):1235-1244. PubMed ID: 33530866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances with antibody-drug conjugates in breast cancer treatment.
    Abdus Subhan M; Torchilin VP
    Eur J Pharm Biopharm; 2021 Dec; 169():241-255. PubMed ID: 34748933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Not Available].
    Mallet A; Ombline C; Robert M; Campone M; Frenel JS
    Bull Cancer; 2021 Dec; 108(11S):11S19-11S25. PubMed ID: 34969512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy.
    Kang JC; Sun W; Khare P; Karimi M; Wang X; Shen Y; Ober RJ; Ward ES
    Nat Biotechnol; 2019 May; 37(5):523-526. PubMed ID: 30936563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.
    de Goeij BE; Peipp M; de Haij S; van den Brink EN; Kellner C; Riedl T; de Jong R; Vink T; Strumane K; Bleeker WK; Parren PW
    MAbs; 2014; 6(2):392-402. PubMed ID: 24492309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment.
    Saini S; Gulati N; Awasthi R; Arora V; Singh SK; Kumar S; Gupta G; Dua K; Pahwa R; Dureja H
    Curr Drug Deliv; 2024; 21(7):993-1009. PubMed ID: 37519200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs.
    Andreev J; Thambi N; Perez Bay AE; Delfino F; Martin J; Kelly MP; Kirshner JR; Rafique A; Kunz A; Nittoli T; MacDonald D; Daly C; Olson W; Thurston G
    Mol Cancer Ther; 2017 Apr; 16(4):681-693. PubMed ID: 28108597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance.
    Yamazaki CM; Yamaguchi A; Anami Y; Xiong W; Otani Y; Lee J; Ueno NT; Zhang N; An Z; Tsuchikama K
    Nat Commun; 2021 Jun; 12(1):3528. PubMed ID: 34112795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
    Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
    Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.